I invested in a clinical trials company many years ago (operating an investigative site), and I'm curious what kind of traction you've gotten from the big pharmaceutical companies?

I totally get how it is a compelling story for investors, but I have serious doubts about adoption and use.

It was my experience that data and sound record keeping was a secondary to approvals. Many times paperwork was "corrected" and patients were excluded because of serious adverse events. Unless your model is to help identify exclusionary criteria retroactively?